Clinical Resources
-
These concise highlights provide the current state of stem cell science for specific diseases, including background on the disease, rationale for using cell-based therapies, evidence for specific approaches and current status of the field with respect to clinical trials. Learn more.
-
A professional standard for information that needs to be provided to patients (or their legally valid surrogates) to help them make an informed decision if offered stem cell-based interventions outside of a formal clinical trial. Learn more.
-
A professional standard for information to be provided to women who, after making a final decision to have a planned pregnancy termination, have expressed interest in donating tissue from the fetal remains. Learn more.
-
background and fundamental questions for clinicians and ethics/institutional review committees to ask when considering running or reviewing early phase, cell-based clinical trials. Learn more.
Disease Fact Sheets
Concise highlights providing the current state of stem cell science for specific diseases, including background on the disease, rationale for using cell-based therapies, evidence for specific approaches and current status of the field with respect to clinical trials. Information for patients and the public on how stem cells are being used to treat some diseases can be found at About Stem Cells.
-
Clinical Status: Cell based therapy using embryonic stem (ES) cell-derived RPE transplantation was first tested in dry AMD, followed by two clinical investigations of ES- and induced pluripotent stem (iPS) cell derived RPE sheet transplantation for wet AMD. These studies have shown that pluripotent stem cell derived-RPE transplantation can be done safely and is feasible. The efficacy of this approach is still being investigated and will determine whether this therapy becomes a standard of care for this condition.
-
Clinical Status: There are no clinical trials aimed at replacing the motor neurons lost in ALS. However, there are completed and ongoing trials using stem cells to modulate disease progression in ALS. These trials have generally used bone marrow-derived mesenchymal stem cells (MSCs), which are typically expanded in culture and then transplanted into the cerebral spinal fluid (CSF). Other approaches, such as injections of human fetal spinal cord-derived neural stem cells and genetically engineered neural progenitor cells releasing GDNF, have also reached clinical trials. Additionally, there has been a small Phase 1 trial using autologous Tregs. Download the ALS Fact Sheet to learn more information about these trials and find additional resources.
-
Clinical Status: While cell-based therapy could become a viable treatment option for clinical application for lung disease in the future, there is no definitive evidence that these cells have a therapeutic benefit. Furthermore, there are still many significant factors to be considered in any future trials such as the best source of MSCs; the route of administration and the most effective dose to trial before MSC administration is considered a safe and effective treatment option. More basic research is needed to further develop the possible use of epithelial cells as a cell-based therapy for lung disease, even before clinical trials can be done.
At present there are no licensed cell-based therapies for lung diseases in the U.S or globally (Ikonomou et al 2019; Sipp et al. 2017). It is critical that patients are well informed regarding the current lack of efficacious cell-based therapeutic options. Patients considering such treatments need to understand that current cell-based therapies for lung disease are unproven, experimental, and are not under appropriate regulatory oversight.
-
Clinical Status: At present, clinical cell-based therapies in the form of islets obtained from cadaveric pancreases can provide benefit for only a very small number of people with diabetes. New cell-based therapies being developed must be tested in rigorous clinical trials that comply with regulatory standards, such as those by the US Food and Drug Administration. Some clinical trials which have been approved by regulators are underway in which insulin producing cells derived from ESCs are being placed into encapsulation devices and transplanted into human subjects with T1D, but clinical benefit has not yet been reported. There have been a variety of claims in recent years of beneficial results from unregulated transplants using a patient’s own adult stem cells, but these approaches are not supported by a current understanding of science and lack independent and objective efficacy data. These treatments and the clinics offering them should be avoided.
-
Clinical Status: To date, there is no effective treatment for HD. Over the past few years, researchers have focused on both the role of neuronal and glial dysfunction in causing neuronal and synaptic dysfunction of HD. As a result, both neural and glial transplantation-based strategies, using progenitor cells produced from human pluripotent stem cells, are under intensive preclinical development. These studies have strongly suggested the therapeutic potential of a cell replacement strategy in HD, whether accomplished by neural or glial progenitor cells. As a result, efforts are now underway in several centers to produce clinically appropriate populations of both neural and glial progenitor cells for intracerebral transplantation in symptomatic HD patients.
-
Clinical Status: There have been several cell-based clinical studies for liver disease of various types including acute and metabolic liver disease as well as liver cirrhosis. There have been encouraging clinical results from hepatocyte transplantation for a variety of metabolic liver diseases such as Crigler Najjar, glycogen storage disease type 1, and Urea cycle disorders (Iansante et al.). Hepatocyte supply is a challenge and new sources of hepatocytes would have an impact in this area. Currently, for liver cirrhosis there is no clear evidence that cell therapy works. There have been a number of small studies that have shown some possible benefit but larger randomised controlled trials have so far failed to show positive outcomes (Moore et al., Newsome et al.). As such, treating cirrhosis with cell therapies cannot be recommended outside of properly funded clinical trials.
-
Clinical Status: The provision of new, healthy glial progenitor cells, which give rise to new myelin-producing oligodendrocytes, is under development as a potential treatment strategy, with the tandem goals of stabilizing disease by preventing further neuronal loss and restoring function by remyelinating demyelinated neuronal axons. In preclinical work thus far, methods have been developed for producing large numbers of homogeneous, deliverable human glial progenitor cells from pluripotent human stem cells, including both embryonic and induced pluripotent stem cells. These cells have proven effective at remyelinating white matter lesions in a variety of both postnatal and adult animal models of acquired demyelination; their potential use as cellular reagents for treating PMS is under review by the FDA.
-
Clinical Status: Clinical trials began in the early 2000s with transplantation of bone marrow stem cells, followed by cells derived from adult hearts. These trials demonstrated that cell therapy for acute MI or chronic heart failure is feasible and generally safe for patients. Early trials with small numbers of patients suggested the possibility of improved cardiac function but as the field moved into larger trials that were randomized, blinded, and placebo-controlled, there were fewer indications of improved function. Taken together, the consensus now is that adult cells have only modest, if any, benefit to cardiac function (Eschenhagen et al, 2017). The first trials of human pluripotent stem cell derivatives were recently performed, with “patches” of human cardiac cells placed onto the surface of the failing heart (Menasché et al, 2018). Early results suggest that this approach is feasible and safe, but it is too early to know whether there are functional benefits.
-
Clinical Status: Cell therapies to treat human OA are used worldwide without clear support from high quality studies. In the United States, cell therapies for OA primarily involve the use of cells obtained from autologous and minimally manipulated tissues such as concentrated bone marrow aspirate and adipose stromal vascular fraction. A recent review of the English language literature on cell therapies for knee OA revealed only 3 studies involving small numbers of patients with differing methodologies, low serious adverse events, and mixed clinical outcomes (Chahla et al, 2016). One study injecting marrow-derived cells into the knees of patients with OA showed no serious adverse events but outcomes similar to saline injection (Shapiro et al, 2017). Limited international studies on the use of allogenic culture expanded MSC in knee OA showed improvement in joint pain and swelling in some studies but with no to mild symptomatic improvement (Gupta et al, 2016 and Pers et al, 2016). Overall, high quality studies evaluating the effectiveness of cell therapies in the treatment of knee OA are lacking.
-
Clinical Status: Over the last 15 years, technologies and protocols have evolved to the point that midbrain dopamine neurons can now be made from both embryonic stem (ES) and induced pluripotent stem (iPS) cell sources, which show good survival in animal models of PD and demonstrate functional benefits. This work has progressed to the point where the first in-human clinical trials have started. The first one was initiated at Kyoto University in Japan 2018. Similar clinical trials using ES cells have also been initiated in both the USA and Europe. The USA trial conducted by BlueRock Therapeutics has been completed and showed that the approach was well tolerated with no major safety issues and with some early signs of graft survival and effect. A phase 2 trial is planned. In Europe, the STEM-PD trial, an academic trial involving Lund University/University Hospital in Sweden and Cambridge University/University Hospital in UK was initiated in 2023 and is still ongoing. In addition, a single case report of a patient receiving autologous iPSC-derived dopamine cells has been published. Download the PD Fact Sheet to learn more information about these trials and find additional resources.
-
Clinical Status: Currently, most patients with LDs can only be offered supportive treatment; few disease-modifying or curative strategies are available. Metabolic LDs due to enzymatic dysfunction, including the lysosomal storage diseases such as globoid cell leukodystrophy, and peroxisomal disorders like drenoleukodystrophy, may be offered HSCT/USCT. However, the benefits of this approach are limited to mild and early-diagnosed cases; this approach cannot restore cells already lost, or repair damage that has already occurred. For that purpose, cell replacement therapy with human neural or glial progenitor cells is under development. This approach was first trialed in a phase I safety study in patients with Pelizaeus-Merzbacher disease, a congenital leukodystrophy characterized by mutations in the gene coding proteolipid protein (PLP), which is required for myelination. This study provided the first proof of principle that human NPCs transplanted into the cerebral white matter are well tolerated and could engraft the white matter of affected children. Yet the use of fetal tissue-derived cells hindered the further development of this strategy. As a result, more recent efforts have focused on the use of glial progenitor cells derived from human pluripotent stem cells.
Informed Consent Standard for Stem Cell-Based Interventions
This document outlines a professional standard for the information that needs to be provided to patients (or their legally valid surrogates) to help position them to make an informed decision if offered stem cell-based interventions outside of a formal clinical trial. Stem cell-based interventions are complex and come with unique risks. The Consent Standard specifies the information that must be disclosed during the informed consent process, prior to administering any stem-cell based intervention outside of a clinical trial. Anyone offering stem cell-based interventions outside of a formal clinical trial should include these elements, along with anything else required by applicable laws, policies, practices, and regulations for informed consent.
Download full PDF:
Informed Consent Standard for Human Fetal Tissue Donation for Research
This document outlines a professional consent standard for the donation of human fetal tissue for any field of research. The information described in this standard should be provided to women who, after making a final decision to have a planned pregnancy termination, have expressed interest in donating tissue from the fetal remains.
Download full PDF:
Practical Advice for Physicians and Ethics / Institutional Review Committees
Stem cell-derived cellular interventions require a unique set of considerations that differ from those used to assess pharmacological drugs, so it’s essential that the physicians that run them and the ethics / institutional review boards that approve them are familiar with the appropriate questions to ask. The ISSCR's "Stem Cell-Based Clinical Trials: Practical Advice for Physicians and Ethics/Institutional Review Committees" provides background and fundamental questions for clinicians and ethics / institutional review committees to ask when considering running or reviewing early phase, cell-based clinical trials. The guide was developed by practicing physician-scientists and stem cell professionals on the ISSCR’s Clinical Translation Committee.